Skip to main content

Table 3 Main clinical characteristics of the study population

From: Budd-Chiari syndrome: epidemiological and clinical characteristics of a case series in Northwest Spain

 

Sex

Age

Risk factor

Course

Hb (g/dL)

Platelets (x109/L)

Fg (mg/dL)

Alb (g/dL)

TBIL (mg/dL)

Anticoagulation

Intervention

Outcome

1

Male

68

Suspected polycythaemia vera, not confirmed

Acute hepatitis

19.9

205

294

3.0

9.7

LMWH

TIPS

Died

2

Male

54

Multiple myeloma

Acute hepatitis

10.2

81

608

3.0

2.8

None

Mechanical thrombectomy

Died

3

Male

39

Paroxysmal nocturnal haemoglobinuria

Subacute hepatitis

9.7

66

427

NA

2.1

LMWH

TIPS

Survived

4

Male

21

Leukaemia

Acute hepatitis

15.8

196

301

4.2

1.1

UH

Mechanical thrombectomy

Died

5

Female

78

Hepatocarcinoma

Cirrhosis

12.5

105

325

2.9

0.8

None

None

Died

6

Female

84

Cirrhosis

Cirrhosis

9.6

119

335

2.4

1.4

LMWHa

None

Died

7

Female

43

Ovarian cancer

Acute hepatitis

9.3

206

511

2.7

1.1

LMWH

None

Survived

8

Female

73

Liver abscess

Subacute hepatitis

12.1

184

NA

3.3

0.6

LMWH

None

Survived

9

Male

27

Not identified

Subacute hepatitis

13.9

169

450

4.3

2.0

LMWH

None

Survived, developed cirrhosis

10

Female

39

Factor V Leiden mutation

Subacute hepatitis

13.5

226

407

4.6

0.4

None

None

Survived

11

Female

79

Liver abscess

Subacute hepatitis

10.2

464

333

3.3

1.7

LMWH

None

Died

12

Male

75

Colorectal cancer

Acute hepatitis

10.2

194

676

2.3

0.9

LMWH

None

Died

13

Female

29

Antiphospholipid syndrome and systemic lupus erythematosus

Subacute hepatitis

8.9

81

568

3.0

0.3

LMWHa

None

Survived

14

Male

51

Colorectal cancer and liver abscess

Subacute hepatitis

11.6

726

715

2.7

0.6

LMWH

None

Survived

15

Male

49

Liver abscess

Subacute hepatitis

12.4

299

465

3.4

0.7

LMWH

None

Survived

  1. Hb, haemoglobin; Fg, fibrinogen; Alb, albumin; TBIL, total bilirubin; LMWH, low molecular weight heparin; UF, unfractionated heparin; TIPSS, transjugular intrahepatic portosystemic shunt
  2. aTransition to acenocoumarin after 2 weeks of LMWH